[EN] PROCESS FOR THE PRODUCTION OF TETRAAMINOBIPHENOL MACROCYCLIC LIGANDS; AND NOVEL TETRAAMINOBIPHENOL MACROCYCLIC LIGANDS<br/>[FR] PROCÉDÉ DE PRODUCTION DE LIGANDS MACROCYCLIQUES DE TÉTRAAMINOBIPHÉNOLE ; ET NOUVEAUX LIGANDS MACROCYCLIQUES DE TÉTRAAMINOBIPHÉNOLE
申请人:ECONIC TECH LTD
公开号:WO2018158592A1
公开(公告)日:2018-09-07
A process for preparing a tetra-substituted aminobiphenol macrocyclic ligand having the structure (I), comprising the step of treating a precursor compound having the structure (II) with a compound having the structure R6-L where L represents a leaving group (hereinafter compound (III)) in the presence of a base; wherein R1 and R2 are independently selected from hydrogen, halide, a nitro group, a nitrile group, an imine group, -NCR13R14, an amine, an ether group -OR1 5 or -R16OR17, an ester group -OC(O)R10 or - C(O)OR10, an amido group -NR9C(0)R9 or -C(0)-NR9(R9), -COOH, -C(0)R15, -OP(0)(OR18)(OR19),- P(O)R2 0R21, a silyl group, a silyl ether group, a sulfoxide group, a sulfonyl group, a sulfinate group or an acetylide group or an optionally substituted alkyl, alkenyl, alkynyl, haloalkyl, aryl, heteroaryl, alkoxy, aryloxy, alkylthio, arylthio, alicyclic or heteroalicyclic group; R3 is independently selected from optionally substituted alkylene, alkenylene, alkynylene, heteroalkylene, heteroalkenylene, heteroalkynylene, arylene, heteroarylene or cycloalkylene, wherein alkylene, alkenylene, alkynylene, heteroalkylene, heteroalkenylene and heteroalkynylene, in each case optionally interrupted by aryl, heteroaryl, alicyclic or heteroalicyclic; R4 is independently selected from hydrogen, or optionally substituted aliphatic, heteroaliphatic, alicyclic, heteroalicyclic, aryl, heteroaryl, alkylheteroaryl or alkylaryl; R5 is independently selected from hydrogen, optionally substituted aliphatic, heteroaliphatic, alicyclic, alkanoate, arylate, carboxyl, heteroalicyclic, aryl, heteroaryl, alkylheteroaryl or alkylaryl, or two R5 species may together be selected from optionally substituted alkylene, alkenylene or alkynylene, bonded to two different N groups of the compound of structure (II), with the proviso that at least one of the species R5 is hydrogen; and E is independently selected from NR5 and NR6, with the proviso that at least one of the species E is NR6; wherein R6 is independently selected from optionally substituted aliphatic, alicyclic, heteroalicyclic, aryl, heteroaryl, ether, polyether, or optionally substituted alkylaryl or alkylheteroaryl; wherein R9, R10, R13, R14, R18, R19, R20 and R21 are independently selected from hydrogen or an optionally substituted aliphatic, heteroaliphatic, alicyclic, heteroalicyclic, aryl or heteroaryl group and R15, R16 and R17 are independently selected from an optionally substituted aliphatic, heteroaliphatic, alicyclic, heteroalicyclic, aryl or heteroaryl group; and wherein the molar ratio of compound (III) to the number of NH sites in the compound of structure (II) is at least 0.6. In embodiments of the invention the molar ratio of compound (III) to species R5 which are hydrogen in compound (II) is at least 1. Surprisingly, it has been determined that N-alkylation of the compound of structure (II) takes place efficiently despite the presence of phenol groups would be expected to be sites for O-alkylation. Also described are certain novel ligands having asymmetrical R5 and R6 groups.
一种制备具有结构(I)的四取代氨基联苯环状配体的方法,包括以下步骤:在碱的存在下,用具有结构(II)的前体化合物与具有结构R6-L的化合物(以下简称化合物(III))反应;其中R1和R2分别选择自氢、卤素、硝基、腈基、亚胺基、-NCR13R14、胺基、醚基-OR15或-R16OR17、酯基-OC(O)R10或-C(O)OR10、酰胺基-NR9C(0)R9或-C(0)-NR9(R9)、-COOH、-C(0)R15、-OP(0)(OR18)(OR19)、-P(O)R20R21、硅基、硅醚基、亚砜基、磺酰基、磺酸盐基或乙炔基或可选择取代的烷基、烯基、炔基、卤代烷基、芳基、杂环芳基、烷氧基、芳氧基、烷硫基、芳硫基、脂环或杂环脂基;R3从可选择取代的烷基、烯基、炔基、杂烷基、杂烯基、杂炔基、芳基、杂芳基或环烷基中独立选择,其中烷基、烯基、炔基、杂烷基、杂烯基和杂炔基,每种情况下可由芳基、杂芳基、脂环或杂环脂中断;R4从氢或可选择取代的脂肪、杂脂肪、脂环、杂环脂、芳基、杂芳基、烷基杂芳基或烷基芳基中独立选择;R5从氢、可选择取代的脂肪、杂脂肪、脂环、烷酸酯、芳酸酯、羧基、杂环脂、芳基、杂芳基、烷基杂芳基或烷基芳基中独立选择,或两个R5物种可以共同选择自可选择取代的烷基、烯基或炔基,与结构(II)化合物的两个不同N基团结合,条件是至少有一个R5物种是氢;E从NR5和NR6中独立选择,条件是至少有一个E物种是NR6;其中R6从可选择取代的脂肪、脂环、杂环脂、芳基、杂芳基、醚、聚醚或可选择取代的烷基芳基或烷基杂芳基中独立选择;其中R9、R10、R13、R14、R18、R19、R20和R21从氢或可选择取代的脂肪、杂脂肪、脂环、杂环脂、芳基或杂芳基中独立选择,R15、R16和R17从可选择取代的脂肪、杂脂肪、脂环、杂环脂、芳基或杂芳基中独立选择;化合物(III)与结构(II)化合物中NH位点的摩尔比至少为0.6。在发明实施例中,化合物(III)与结构(II)中为氢的R5物种的摩尔比至少为1。令人惊讶的是,尽管苯酚基被认为是O-烷基化的位置,但已确定结构(II)化合物的N-烷基化有效进行。还描述了具有不对称R5和R6基团的某些新型配体。